Citius Pharmaceuticals (CTXR)

• Market cap: $15.1M
• 1 day: -1.03%
• 5 days: -5.14%
• 1 month: -13.84%
• 3 months: -40.9%
• 6 months: -52.97%
• Year to date: -35.12%
• 1 year: -48.09%
• 5 years: -99.12%
• 10 years: -99.29%
• Sector: Healthcare
• Industry: Biotechnology

About: Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.

Employees: 23